Novavax, Inc. (NVAX) announced that Health Canada has granted expanded authorization for Nuvaxovid for active immunization to prevent coronavirus disease 2019 caused by SARS-CoV-2 as a homologous booster in adults aged 18 and older. The company said the expanded authorization was based on data from a phase 2 trial conducted in South Africa and from the Prevent-19 phase 3 trial conducted in the U.S. and Mexico.
Health Canada previously authorized Nuvaxovid as a primary series in adults aged 18 and older in February 2022.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News